Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma

Inclusion Criteria: * Patients diagnosed with histologically or cytologically proven, CD 20+, diffuse large B-cell lymphoma, * Relapse after first or second CR, PR or less than PR to first-line treatment for the rituximab-naïve patients, OR relapse after first or second CR with a minimum delay of 12 months between the last rituximab infusion and the inclusion for the rituximab-experienced patients * Aged 18 - 75 years * Not eligible for autologous transplantation * Previously treated with chemotherapy containing anthracycline, with or without rituximab * ECOG performance status 0 to 2 * With a minimum life expectancy of 3 months * Having signed informed consent form prior to enrollment Exclusion Criteria: * Burkitt's, mantle cell, T-cell lymphomas * CD 20-negative lymphoma * HIV or HBV related disease * Central nervous system or meningeal involvement by the lymphoma * Not previously treated with anthracycline-containing regimens * Contraindication to any drug contained in the R-GEMOX chemotherapy regimen * Any serious active disease or co-morbid medical condition (according to the investigator's decision), * Poor renal function (creatinine level \> 150micromol/l), poor hepatic function (total bilirubin level \> 30mmol/l, transaminases \> 2.5 maximum normal level) unless these abnormalities are related to the lymphoma * Poor bone marrow reserve as defined by neutrophils \< 1.5 G/l or platelets \< 100 G/l, unless related to bone marrow infiltration * Any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma * Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study * Any radiotherapy during the four weeks before inclusion * Pregnant or lactating woman * Adult patient unable to give informed consent because of intellectual impairment.